$FEMY News

Femasys Regains Compliance with Nasdaq Listing Requirements

Femasys Announces 1-For-20 Reverse Stock Split, Effective June 5

Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter

Femasys Announces CE Mark Approval For FemHSG Catheter, Further Expanding Its Portfolio In Europe Through Commercial Partners

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

Femasys Announces First Revenue-Generating Commercial Use Of Its Fertility Portfolio In An OBGYN Setting, Led By FemaSeed As A First-Line Infertility Treatment

Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026

Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio

Femasys Collaborates With AMI Technologies To Roll Out, Commercialize Fertility Portfolio In Israel

Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth

Femasys Appoints John Canning COO

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Femasys Q4 EPS $(0.06) Beats $(0.12) Estimate, Sales $813.387K Miss $1.450M Estimate

Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

Femasys Initiates Participant Enrollment In FINALE Pivotal Clinical Study Of FemBloc

Lake Street Initiates Coverage On Femasys with Buy Rating, Announces Price Target of $1.5

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access